Mounjaro No — What the Evidence Says About Who It Isn't Right For

What the NICE guidance and SmPC say about who shouldn't use tirzepatide

The NICE recommendation for tirzepatide (TA1026, updated September 2025) sets out a clear eligibility frame: adults with a BMI of 35 or above plus at least one weight-related comorbidity, with lower thresholds applying for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. The licensed use approved by the MHRA is slightly broader (BMI 30 or above, or 27 or above with a qualifying condition) but the SmPC also lists the circumstances in which the medicine must not be used at all.

Those hard contraindications include a personal or family history of medullary thyroid carcinoma, a diagnosis of Multiple Endocrine Neoplasia syndrome type 2, and a history of serious hypersensitivity to tirzepatide or any of the pen's components. A history of pancreatitis requires careful prescriber discussion, many clinicians would not start tirzepatide where there has been a prior episode. People with severe gastrointestinal conditions, including gastroparesis, also fall outside the usual candidate profile.

Pregnancy is a firm no. Mounjaro is not recommended during pregnancy, while breastfeeding, or in the months before trying to conceive, because the effects on fetal development are not fully established and adequate contraception during treatment is advised. Tirzepatide can reduce the absorption of oral contraceptives in the first weeks of treatment and after each dose step up, so women using the pill should add a non-oral method during those windows, and that conversation with a prescriber should happen before treatment begins, not after. The medicine is also not licensed for anyone under 18.

When a "no" from a GP or online service reflects something fixable

A significant number of "no" answers are conditional rather than absolute. A GP might decline to prescribe because the practice isn't yet participating in the NHS tirzepatide prescribing scheme, which rolled out to primary care from April 2026 but remains optional for individual practices. That's a system constraint, not a clinical one, and if you're wondering whether getting Mounjaro without a GP referral is possible, it's worth understanding before concluding the medicine is unsuitable for you personally.

An online pharmacy might decline because a consultation response flagged something that needs clarifying: uncontrolled blood pressure, a recent cardiac event, or a drug interaction with an existing medicine. Some of those situations resolve once the underlying issue is addressed. Others (type 1 diabetes, for instance, or active eating-disorder history) warrant a more careful conversation about whether weight-loss medicines are the right route at all, and a specialist opinion may be more useful than another online consultation. If you're unsure why a previous service said no, asking for the specific reason in writing is a reasonable thing to do. Our frequently asked questions cover what happens when a consultation doesn't result in approval.

It's also worth being honest that a refusal can feel frustrating, especially after weeks on an NHS waiting list or months trying to get a GP appointment. That frustration is completely understandable. The prescriber's job, though, is to assess your individual situation, not to approve applications. A no that keeps you safe is the right outcome, even when it doesn't feel that way.

What the SURMOUNT trial evidence shows about who responds, and who doesn't

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no type 2 diabetes. Average weight loss reached around 20–21% at the 15mg maintenance dose over 72 weeks. That's a strong signal, but it was produced in a population that met the trial's inclusion criteria, people who had been excluded because of contraindications weren't in those numbers. Trial evidence tells us what the medicine can do for the right candidate; it doesn't override the clinical reasons a particular person shouldn't use it.

NICE's own modelling, published alongside TA1026, estimated that people who lose less than 5% of their starting weight after six months at the highest tolerated dose are unlikely to be long-term responders, and continuing in that scenario would be reviewed. A lack of response at a lower dose isn't the same as a permanent no, it may indicate that titration hasn't reached the therapeutic level yet, or that lifestyle factors need addressing alongside the medicine. If you've been on Mounjaro for a while and aren't seeing the expected progress, the guide to limited response on tirzepatide covers that in more detail, and the answer is usually to review the dose with a prescriber rather than stop altogether.

For context on how the broader treatment landscape fits together (including whether a different licensed medicine might suit you better) the weight-loss treatment overview is a good starting point. Cost considerations are covered separately on the Mounjaro pricing page, since for some people the answer isn't "medically no" but "practically difficult right now."

How nume's prescribers approach a borderline consultation

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not an automated scoring system) on the same day it's submitted. That means borderline cases get considered as individual pictures rather than pass/fail data sets. Where the answer is no, the prescriber sets out why, and in many cases that note opens a path: a condition to stabilise, a GP to loop in, an alternative medicine to consider. Some patients also ask about hormonal changes during treatment, and our page on what to do if your period stops on Mounjaro is one example of how side-effect questions are addressed alongside the core prescribing process.

Photo-ID verification, live weight confirmation on video, and Summary Care Record checks where appropriate are all part of the process, not bureaucracy for its own sake, but the infrastructure that makes a safe yes (and a meaningful no) possible. If you want to find out where you stand, the Mounjaro yes or no eligibility guide steps through the criteria in plain language before you submit anything. And if you decide you'd like a prescriber to assess your situation properly, you can start your free consultation with no obligation. The consultation itself is the assessment, the outcome depends on you.